新日本製薬(株)の貸借残高情報
主市場 | 業種 | 証券コード/EDINET | 英名称 |
---|
東証PRM | 化学 | 4931/ - | - |
公表日 | 公表 | 貸付残高 | 前週比 | 新規貸付成約高 | 前週比 | 借入残高 | 前週比 | 新規借入成約高 | 前週比 |
---|
2022/04/01 | 日証協 | 306,324株 | +3.62% | 90,196株 | -52.26% | 436,036株 | +1.76% | 175,834株 | +554.05% |
2022/03/25 | 日証協 | 295,610株 | -4.28% | 188,924株 | -14.26% | 428,494株 | -2.92% | 26,884株 | -62.91% |
2022/03/18 | 日証協 | 308,819株 | +28.36% | 220,351株 | +45.65% | 441,392株 | +10.35% | 72,482株 | +89.25% |
2022/03/11 | 日証協 | 240,590株 | -0.99% | 151,290株 | +71.45% | 399,991株 | -0.44% | 38,300株 | -37.65% |
2022/03/04 | 日証協 | 242,990株 | +2.03% | 88,244株 | +28.28% | 401,773株 | +7.97% | 61,424株 | +53.3% |
2022/02/25 | 日証協 | 238,163株 | +5.91% | 68,788株 | -44.52% | 372,122株 | +3.96% | 40,069株 | -49.05% |
2022/02/18 | 日証協 | 224,863株 | +9.84% | 123,985株 | +2.11% | 357,947株 | +12.41% | 78,642株 | +23.04% |
2022/02/10 | 日証協 | 204,715株 | -26.69% | 121,427株 | +72.73% | 318,422株 | -15.02% | 63,918株 | +289.22% |
2022/02/04 | 日証協 | 279,258株 | -5.03% | 70,300株 | +64.64% | 374,691株 | +0.35% | 16,422株 | -13.58% |
2022/01/28 | 日証協 | 294,058株 | -9.12% | 42,700株 | -62.41% | 373,369株 | -0.74% | 19,002株 | -91.85% |
2022/01/21 | 日証協 | 323,569株 | -17.79% | 113,600株 | -28.28% | 376,167株 | -10.17% | 233,237株 | +109.91% |
2022/01/14 | 日証協 | 393,596株 | -20.01% | 158,394株 | -3.22% | 418,755株 | -11.43% | 111,111株 | +198.68% |
2022/01/07 | 日証協 | 492,066株 | -9.41% | 163,658株 | +13.52% | 472,774株 | -7.6% | 37,201株 | -35.64% |
2021/12/30 | 日証協 | 543,197株 | 0% | 144,163株 | 0% | 511,686株 | 0% | 57,802株 | 0% |
2021/12/24 | 日証協 | 543,197株 | -3.22% | 144,163株 | +62.43% | 511,686株 | -1.97% | 57,802株 | +83.85% |
2021/12/17 | 日証協 | 561,288株 | -7.14% | 88,752株 | -72.32% | 521,985株 | -7.91% | 31,440株 | -82.62% |
2021/12/10 | 日証協 | 604,473株 | +16.56% | 320,603株 | +60.62% | 566,835株 | +9.22% | 180,916株 | +72.92% |
2021/12/03 | 日証協 | 518,588株 | -24.32% | 199,609株 | +83.25% | 518,985株 | -23.28% | 104,627株 | +316.66% |
2021/11/26 | 日証協 | 685,200株 | -11.09% | 108,926株 | -85.77% | 676,480株 | -10.55% | 25,111株 | -89.48% |
※株式分割は考慮していませんのでご注意ください。
Page Top